Related Experiment Video
Updated: Sep 22, 2026

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
Medication Use and Risk of Microscopic Colitis: A Propensity-Matched Analysis of US Adults ≥ 50 Years (2014-2024)
Yassine Kilani1, Farah Heis1, Andrew Dugaesescu2
1Division of General Internal Medicine, Department of Internal Medicine, Saint Louis University School of Medicine, St Louis, Missouri, USA.
Background:
The association between medications-including non-steroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs) and selective serotonin reuptake inhibitors (SSRIs)-and microscopic colitis (MC) remains controversial. While earlier studies suggested increased risk, more recent analyses have challenged these findings, citing methodological limitations. We evaluated the risk of MC among commonly implicated medications using a large national U.S.
Methods:
Using the TriNetX database (2014-2024), we conducted a retrospective cohort study including adults ≥ 50 years with at least one documented healthcare encounter and no prior MC or inflammatory bowel disease. Exposure was defined as ≥ 3 prescriptions within a drug class. Treatment groups (NSAIDs, PPIs, SSRIs, ACE inhibitors [ACEIs], angiotensin receptor blockers [ARBs], statins) were 1:1 propensity score-matched (PSM) to untreated controls on age, sex, race, comorbidities and previous colonoscopy. The primary outcome was incident MC, identified by new diagnostic codes. Cox proportional hazards models estimated hazard ratios (HRs) and 95% confidence intervals (CIs).
Results:
After PSM, cohorts included 907,266 NSAID, 750,009 PPI, 308,310 SSRI, 393,952 ACEI, 298,480 ARB users and 548,339 statin users. Over 2 years, MC risk was increased with NSAIDs (HR 1.15; 95% CI, 1.02-1.30), PPIs (HR 1.36; 95% CI, 1.19-1.54) and SSRIs (HR 1.52; 95% CI, 1.27-1.83). ACEIs, ARBs and statins were not associated with MC.
Conclusions:
In this large cohort, NSAIDs, PPIs and SSRIs were associated with an increased risk of MC, whereas no significant association was observed for ACEIs, ARBs or statins. Medication review should be considered in patients with new-onset chronic diarrhoea.
More Related Videos
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
06:55Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Therapeutic Drug Monitoring: Affecting Factors
Drug Dosing: Geriatric Patients
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Microbiota Modulation by Antibiotics